Concizumab prophylaxis for haemophilia A or B without inhibitors: a plain language summary of the phase 3 explorer8 study

Future Rare Diseases · Published 2026-06-11 · DOI 10.1080/23995270.2026.2664412

Free full text

Authors (4)

Mark W. Skinner, Hermann Eichler, Pratima Chowdary, Glenn F. Pierce

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year

2026

Citation

Skinner, M., Eichler, H., Chowdary, P., et al. (2026). Concizumab prophylaxis for haemophilia A or B without inhibitors: a plain language summary of the phase 3 explorer8 study. Future Rare Diseases. https://doi.org/10.1080/23995270.2026.2664412

Related articles

• How I treat Rett syndrome: impact of trofinetide on symptoms and comorbidities of the disease · Future Rare Diseases · 2026 · Same journal
• Physician perspectives on practical implementation of identification & diagnosis of ATTRv-PN Amyloidosis: A case vignette series · Future Rare Diseases · 2025 · Same journal
• Plain language summary: Patient journey and treatment patterns in progressive pulmonary fibrosis · Future Rare Diseases · 2025 · Same journal
• AIRLEAF ® –a study of verducatib as a new kind of treatment for bronchiectasis: a plain language summary · Future Rare Diseases · 2025 · Same journal
• Gastrointestinal symptoms and healthcare utilization among individuals with Rett syndrome at a center of excellence · Future Rare Diseases · 2025 · Same journal
• A plain language summary of the phase 3 explorer7 study of concizumab prophylaxis for people with hemophilia with inhibitors · Future Rare Diseases · 2025 · Same journal
• How I treat Rett syndrome with trofinetide: changes in dosing frequency and administration with rice cereal · Future Rare Diseases · 2025 · Same journal
• rIX-FP prophylaxis in patients with hemophilia B · Future Rare Diseases · 2025 · Same journal
• Plain language summary of a Phase II study design to test different doses of BI 1819479 in people with idiopathic pulmonary fibrosis · Future Rare Diseases · 2025 · Same journal
• Pegcetacoplan for C3G and other complement-mediated glomerular diseases: plain language summary of the DISCOVERY study · Future Rare Diseases · 2025 · Same journal